Jefferies Maintains Buy on Protagonist Therapeutics (PTGX) PT $121 Mar 2026

PTGX analyst rating: On March 18, 2026 Jefferies maintained a Buy on Protagonist Therapeutics, Inc. (PTGX) and raised its price target to $121. The same day Johnson Rice kept a Buy stance and highlighted Truist’s royalty model that projects $730,000,000 peak Icotyde revenue. These dual maintenances reinforce analyst confidence ahead of commercial milestones and show aligned sentiment from a large and a boutique firm.

PTGX analyst rating: Details of the March 18, 2026 actions by Jefferies and Johnson Rice

Jefferies on March 18, 2026 maintained Buy and raised its price target to $121. Read the full note at StreetInsider.

Johnson Rice on March 18, 2026 also maintained Buy, citing modeling from Truist projecting $730,000,000 peak Icotyde royalties. See the coverage at StreetInsider.

PTGX analyst rating: What the maintained Buy ratings mean for investors

Both firms keeping Buy shows they expect material upside versus current valuation. Investors should view the calls as analyst confidence in revenue pathways, especially Icotyde royalties.

Maintained ratings mean analysts see execution and commercial risks as manageable, not that the stock is without risk. Use the ratings with company fundamentals and pipeline milestones.

PTGX analyst rating: Price targets, market reaction, and performance signals

Jefferies’ $121 target and Johnson Rice’s bullish modeling coincided with reported price moves of 6.02% ($5.89) and 6.14% ($6.00) since their mentions. These moves indicate the market priced in renewed optimism quickly.

Protagonist’s market cap stands at $6,615,047,929, showing analysts expect growth against a large valuation base. Active traders will watch volume and volatility after such analyst updates.

PTGX analyst rating: Historical analyst coverage and context

Protagonist has drawn periodic analyst attention tied to pipeline events and partnerships. Large firms like Jefferies carrying coverage adds institutional credibility.

Smaller specialized teams, including Johnson Rice, often focus on royalty and commercial forecasts. Together they give a fuller picture of near-term revenue and long-term upside.

PTGX analyst rating: Key risks and catalysts tied to the ratings

Analyst confidence rests on Icotyde royalty assumptions and successful commercial execution. Regulatory or commercial setbacks would quickly change views.

Catalysts include royalty receipts, partner disclosures, and quarterly updates. Investors should monitor those items closely after analyst maintenances.

PTGX analyst rating: How to use these ratings with Meyka AI analysis

Meyka AI rates PTGX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Combine the PTGX analyst rating with Meyka AI’s real-time data and your risk tolerance. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

The March 18, 2026 analyst actions leave a clear message: major and specialty firms see upside for Protagonist Therapeutics. Jefferies maintained Buy and set a $121 price target. Johnson Rice maintained Buy while flagging a Truist model that estimates $730,000,000 peak Icotyde royalties. For investors the takeaway is simple: analysts expect revenue drivers to justify current valuation, but outcomes depend on execution and partner royalty flows. Market moves after the notes—single day shifts in the 6% range—show the market reacts to analyst clarity. Use the PTGX analyst rating as one input, alongside company releases, regulatory updates, and Meyka AI’s live metrics. Meyka AI’s B+ grade supports the view of above-average prospects, but not certainty. Balance analyst views with your holding horizon and risk plan, and watch upcoming commercial disclosures closely.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.